Clinical trial
A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg…
NCT00219128 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00219128 |
|---|---|
| Title | A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure. |
| Official title | An Eight-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study Comparing Aliskiren 150 mg, 300 mg, and 600 mg to Placebo in Patients With Essential Hypertension |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension |
| Intervention type | Drug |
| Interventions | aliskiren |
| Enrollment | 671 |
| Start date | Nov 1, 2004 |
| Primary completion | Jun 1, 2005 |
| Completion | Jun 1, 2005 |
| First posted | Sep 22, 2005 |
| Last update posted | Nov 8, 2011 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: